JP2022504298A - Ｂ型肝炎ウイルス疾患の処置および予防のためのフラボン誘導体 - Google Patents

Ｂ型肝炎ウイルス疾患の処置および予防のためのフラボン誘導体 Download PDF

Info

Publication number
JP2022504298A
JP2022504298A JP2021518664A JP2021518664A JP2022504298A JP 2022504298 A JP2022504298 A JP 2022504298A JP 2021518664 A JP2021518664 A JP 2021518664A JP 2021518664 A JP2021518664 A JP 2021518664A JP 2022504298 A JP2022504298 A JP 2022504298A
Authority
JP
Japan
Prior art keywords
chloro
oxo
chromen
phenoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021518664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504298A5 (https=
JPWO2020070088A5 (https=
Inventor
チェン，ドーンドーン
フオン，ソーン
ジアーン，ミン
リウ，ヨーンフゥ
ジョン，ジアミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2022504298A publication Critical patent/JP2022504298A/ja
Publication of JP2022504298A5 publication Critical patent/JP2022504298A5/ja
Publication of JPWO2020070088A5 publication Critical patent/JPWO2020070088A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021518664A 2018-10-03 2019-10-01 Ｂ型肝炎ウイルス疾患の処置および予防のためのフラボン誘導体 Ceased JP2022504298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/109241 2018-10-03
CN2018109241 2018-10-03
PCT/EP2019/076502 WO2020070088A1 (en) 2018-10-03 2019-10-01 Flavone derivatives for the treatment and prophylaxis of hepatitis b virus disease

Publications (3)

Publication Number Publication Date
JP2022504298A true JP2022504298A (ja) 2022-01-13
JP2022504298A5 JP2022504298A5 (https=) 2024-03-04
JPWO2020070088A5 JPWO2020070088A5 (https=) 2024-03-04

Family

ID=68172177

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518664A Ceased JP2022504298A (ja) 2018-10-03 2019-10-01 Ｂ型肝炎ウイルス疾患の処置および予防のためのフラボン誘導体

Country Status (5)

Country Link
US (1) US11708344B2 (https=)
EP (1) EP3860984A1 (https=)
JP (1) JP2022504298A (https=)
CN (1) CN112912371A (https=)
WO (1) WO2020070088A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020052774A1 (en) * 2018-09-14 2020-03-19 F. Hoffmann-La Roche Ag Flavone derivatives for the treatment and prophylaxis of hepatitis b virus disease
WO2020120528A1 (en) * 2018-12-14 2020-06-18 F. Hoffmann-La Roche Ag N-containing chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
JP2022514470A (ja) * 2018-12-14 2022-02-14 エフ．ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を治療および予防するためのクロマン－４－オン誘導体
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504327A (ja) * 1999-07-08 2003-02-04 プレンダーガスト、パトリック、ティ． 感染症の治療を目的としたフラボン類、クマリン類および関連化合物の使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216371D0 (en) 2002-07-13 2002-08-21 Rowett Res Inst The Compounds
CN100415731C (zh) 2004-12-30 2008-09-03 财团法人工业技术研究院 治疗b型肝炎的化合物及其医药组合物
CA2652617A1 (en) 2006-05-19 2007-11-29 The Hong Kong Polytechnic University Flavonoid dimers and methods of making and using such
WO2013127361A1 (en) 2012-03-01 2013-09-06 The Hong Kong Polytechnic University Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers
WO2014074976A1 (en) 2012-11-09 2014-05-15 Musc Foundation For Research Development Compositions and methods for treating neurological diseases or injury
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
WO2015161309A1 (en) 2014-04-19 2015-10-22 Jia Zhou Apigenin analogs, compositions, and methods related thereto
US20210387996A1 (en) 2018-10-24 2021-12-16 Hoffmann-La Roche Inc. Tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504327A (ja) * 1999-07-08 2003-02-04 プレンダーガスト、パトリック、ティ． 感染症の治療を目的としたフラボン類、クマリン類および関連化合物の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACTA PHARMACOLOGICA SINICA, vol. 26, no. 5, JPN6023040158, May 2005 (2005-05-01), pages 587 - 592, ISSN: 0005162220 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 75, JPN6023040157, 2014, pages 267 - 281, ISSN: 0005162221 *

Also Published As

Publication number Publication date
US20230074887A1 (en) 2023-03-09
EP3860984A1 (en) 2021-08-11
WO2020070088A1 (en) 2020-04-09
US11708344B2 (en) 2023-07-25
CN112912371A (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
JP2022504298A (ja) Ｂ型肝炎ウイルス疾患の処置および予防のためのフラボン誘導体
CN109311860B (zh) 用于治疗或预防乙型肝炎病毒疾病的呫吨酮衍生物
JP7839962B2 (ja) Ｂｃｌ－２阻害剤
JP4892649B1 (ja) 縮合環化合物及びその用途
CN110691784A (zh) 抑制mcl-1蛋白的化合物
CN113164571A (zh) 抑制泛素特异性肽酶9x
KR20170078796A (ko) 치환된 크로만 및 이의 사용 방법
TW201400478A (zh) 新醫藥化合物
CN112771032B (zh) 作为第四代egfr抑制剂的嘧啶吡唑类化合物
HK40052612A (en) Flavone derivatives for the treatment and prophylaxis of hepatitis b virus disease
CN113286792B (zh) 用于治疗和预防乙型肝炎病毒感染的含n色烯-4-酮衍生物
CN116390920A (zh) 用于治疗和预防乙型肝炎病毒感染的芳族螺环酰胺衍生物
JP2022500373A (ja) Ｂ型肝炎ウイルス疾患の処置および予防のためのフラボン化合物
JP2022517799A (ja) Ｂ型肝炎ウイルス感染症の処置および予防のための置換されたクロメン－４－オン
CN112996566A (zh) 用于治疗和预防乙型肝炎病毒感染的苯并二氢吡喃-4-酮衍生物
Xu et al. SAR of tricyclic sulfones as γ-secretase inhibitors
HK40091983A (zh) 用於治疗和预防乙型肝炎病毒感染的芳族螺环酰胺衍生物
WO2024249252A1 (en) Methods of using apol1 inhibitors
WO2007055093A1 (ja) 三環性化合物
TW202521109A (zh) 氮聯結苯并異㗁唑磺醯胺衍生物
HK40057573A (en) Chroman-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
HK40059038A (en) N-containing chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
HK40003931B (en) Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
HK40003931A (en) Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
HK1060726B (zh) Vla-4抑制剂

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220929

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231218

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240426

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240823